BioNTech to Report Third Quarter 2024 Financial Results and Corporate Update on November 4, 2024
MAINZ, Germany, October 21, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2024 on Monday, November 4, 2...
BioNTech (BNTX) Presents at Innovation Series: AI Day
BioNTech SE (NASDAQ:BNTX ) Company Conference Call October 1, 2024 9:00 AM ET Company Participants Karim Beguir - Chief Executive Officer, InstaDeep Uğur Şahin - Chief Executive Officer, BioNTech R...
BioNTech BNT116 Lung Cancer mRNA Vaccine Clinical Trials Initiated
Currently More Than 5 Lung Cancer Vaccines Based On mRNA Platform Are Under Clinical Trials Says Kuick Research Currently More Than 5 Lung Cancer Vaccines Based On mRNA Platform Are Under Clinical ...
Lung cancer patient is first in UK to receive experimental vaccine
A lung cancer patient has become the first in the UK to receive a new experimental vaccine to help his body fight the disease.
BioNTech's Loss Quadruples as COVID-19 Vaccine Demand Falls
American depositary receipts (ADRs) of BioNTech (BNTX) fell Monday after the COVID-19 vaccine maker's second-quarter loss quadrupled on falling demand for the shots, and as it ended an agreement wi...
BioNTech widens loss to 807.8 mln euro in second quarter
Losses at Germany's BioNTech quadrupled year-on-year in the second quarter, the company said on Monday, as it banks on a strategy shift towards new cancer treatments following a sharp drop-off in s...
BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patients with Advanced Melanoma
MAINZ, Germany, July 30, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced positive topline data from the ongoing Phase 2 clinical trial (EudraCT No....
BioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024
MAINZ, Germany, July 22, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2024 on Monday, August 5, 2024. ...
BioNTech wins up to $145 mln in CEPI support for African mRNA vaccine plants
COVID-19 vaccine maker BioNTech won up to $145 million in funding from a global coalition against infectious diseases to build a production network in African countries for messenger-RNA based shots.
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024
MAINZ, Germany, May 21, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected programs from the Company's diversified immuno-oncology pipeline...
BioNTech's Outlook Gives Vaccine Maker a Shot in the Arm
American depositary receipts (ADRs) of BioNTech (BNTX) were down less than 1% in intraday trading Monday after the COVID-19 vaccine maker shrugged off losses and tumbling sales in the first quarter...
BioNTech Revenue Falls Sharply on Reduced Covid Vaccine Sales
The pharmaceutical company posts a first-quarter loss of €1.31 a share, a swing from year-earlier profit of €2.05.
Why Earnings Season Could Be Great for BioNTech (BNTX)
BioNTech (BNTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
BioNTech (BNTX) to Report Q1 Earnings: Is a Beat in Store?
On BioNTech's (BNTX) first-quarter 2024 earnings call, investors' focus is likely to be on the updates related to its pipeline development now that the pandemic is over.
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVI...
Related Companies